Health Bulletin 19/September/2022

Published On 2022-09-19 12:10 GMT   |   Update On 2022-09-20 09:27 GMT

Here are the top health news for the day:NCDRC exonerates Cardiologist, Hospital of Negligence in implating pacemaker The National Consumer Disputes Redressal Commission (NCDRC) exonerated a Cardiologist and Manipur based hospital from charges of medical negligence while implanting pacemaker on a patient suffering from Chronic Kidney Disease.Although the District and State Commission had...

Login or Register to read the full article

Here are the top health news for the day:


NCDRC exonerates Cardiologist, Hospital of Negligence in implating pacemaker

The National Consumer Disputes Redressal Commission (NCDRC) exonerated a Cardiologist and Manipur based hospital from charges of medical negligence while implanting pacemaker on a patient suffering from Chronic Kidney Disease.

Although the District and State Commission had held them guilty and directed them to pay Rs 5,90,000 to the Complainants, the top consumer court noted that both the fora had failed to consider the medical grounds and erred to hold the Petitioners liable for medical negligence.

For more details, check out link given below:

NCDRC Exonerates Cardiologist, Hospital Of Negligence In Implating Pacemaker


Sitagliptin, Sitagliptin- Metformin combination to be available at Janaushadhi Kendras at price range of Rs 60 - Rs 100 per pack

Chief Executive Officer of Pharmaceuticals & Medical Devices Bureau of India (PMBI) Shri Ravi Dadhich has launched Sitagliptin a new variant of medicines for diabetes at affordable prices for all under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana. PMBI included new variants of medicines Sitagliptin and its combination in its all Jan Aushdhi Kendras viz.

Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

For more details, check out the link given below:

Sitagliptin, Sitagliptin- Metformin Combination To Be Available At Janaushadhi Kendras At Price Range Of Rs 60 - Rs 100 Per Pack


Alkem Labs secures DCGI nod for launch of StemOne in India

Alkem Laboratories has announced that the company has received approval from the Drug Controller General of India (DCGI) for the launch of StemOne in India. The product is indicated for the treatment of Knee Osteoarthritis. It is the first allogeneic cell therapy product to be approved for commercial use in India for Knee OA.

The product has been developed by Stempeutics, a group company of Manipal Education and Medical Group, over a period of twelve years. More than one million doses can be produced from a single set of master cell banks, which is unique in regenerative medicine, thus providing consistent product to patients.
For more details, check out the link given below:
Provide free treatment to victims of dog bites, Kerala HC directs Govt Hospitals

The Kerala High Court recently passed an order directing the government hospitals and the hospitals attached to government medical colleges to provide prompt, efficient and free medical assistance to all victims of dog bites till the state establishes machinery to contain the menace of stray dogs.

Further, the court comprising bench of Justice A. K. Jayashankaran Nambiar and Justice Gopinath P. J. directed that the treatment should be provided without any prejudice to the right of the person concerned to separately seek compensation from the State for the injuries, mental and/or physical, sustained by him/her, before the appropriate forum.

For more details, check out the link given below:

Provide Free Treatment To Victims Of Dog Bites, Kerala HC Directs Govt Hospitals

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Health Bulletin 01/April/ 2024